Phaseline

Companies › NingBo Junyan Hongshi Biosciences

NingBo Junyan Hongshi Biosciences: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Oncology; next expected readout Jan 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
JS107
anti-CLDN18.2 antibody-drug conjugate
CLDN18Phase 3Gastric AdenocarcinomaJan 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07584135JS107Phase 3Gastric AdenocarcinomaOncologyJan 2029

Targets

CLDN18 (1)

Companies with the same targets

Astellas AstraZeneca RemeGen Shanghai Institute Of Biological Products Beijing Biotech Sichuan Kelun-Biotech Biopharmaceutical Biokin (Shanghai) Biopharmaceutical Transcenta Therapeutics (Hangzhou) Shanghai Hengrui Pharmaceutical Innovent Biologics (Suzhou)

Companies built like this

I-Mab Biopharma US Suzhou Immunofoco Biotechnology LaNova Medicines Zhejiang FutureGen Biopharmaceutical (Beijing) SynOx Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.